In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue ...
Spleen stiffness measurement (SSM) demonstrated strong predictive accuracy for liver decompensation in patients with compensated advanced chronic liver disease (cACLD), with an optimal cutoff of 50 ...
Toxic “forever chemicals” are altering human liver function at a fundamental level by triggering both fat accumulation and cancer-linked cell damage, a new study has found. Several of these compounds, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback